CAR-NK cells, i.e. the Chimeric Antigen Receptor NK Cells, work in the principle of utilizing the donor's NK cells, which are re-engineered in the lab, loaded with receptors recognizing the tumor-antigen, proliferated ex vivo, and subsequently infused to the patient, to recognize and attack the tumor cells. Moreover, NK cells can recognize various ligands through receptors, thereby inhibiting the tumor cells. Hillgene is specialized in provision of integrated CDMO solutions for cellular therapy products, has established a completely closed process development platform for cellular therapy products, and therefore, can provide high-quality CDMO services for cells to clients with various demands.
CAR-NK cells, i.e. the Chimeric Antigen Receptor NK Cells, work in the principle of utilizing the donor’s NK cells, which are re-engineered in the lab, loaded with receptors recognizing the tumor-antigen, proliferated ex vivo, and subsequently infused to the patient, to recognize and attack the tumor cells. Moreover, NK cells can recognize various ligands through receptors, thereby inhibiting the tumor cells. Hillgene is specialized in provision of integrated CDMO solutions for cellular therapy products, has established a completely closed process development platform for cellular therapy products, and therefore, can provide high-quality CDMO services for cells to clients with various demands.
CAR-NK cells, i.e. the Chimeric Antigen Receptor NK Cells, work in the principle of utilizing the donor’s NK cells, which are re-engineered in the lab, loaded with receptors recognizing the tumor-antigen, proliferated ex vivo, and subsequently infused to the patient, to recognize and attack the tumor cells. Moreover, NK cells can recognize various ligands through receptors, thereby inhibiting the tumor cells. Hillgene is specialized in provision of integrated CDMO solutions for cellular therapy products, has established a completely closed process development platform for cellular therapy products, and therefore, can provide high-quality CDMO services for cells to clients with various demands.
CAR-NK cells, i.e. the Chimeric Antigen Receptor NK Cells, work in the principle of utilizing the donor's NK cells, which are re-engineered in the lab, loaded with receptors recognizing the tumor-antigen, proliferated ex vivo, and subsequently infused to the patient, to recognize and attack the tumor cells. Moreover, NK cells can recognize various ligands through receptors, thereby inhibiting the tumor cells. Hillgene is specialized in provision of integrated CDMO solutions for cellular therapy products, has established a completely closed process development platform for cellular therapy products, and therefore, can provide high-quality CDMO services for cells to clients with various demands.
400-900-1882 
info@hillgene.com 
English
![[GMP revised] Appendix for “Investigational Drugs (Interim)” issued and taking effect as of July 1!](/uploads/image/20250603/gmp-revised-appendix-for-investigational-drugs-interim-issued-and-taking-effect-as-of-july-1.webp "[GMP revised] Appendix for “Investigational Drugs (Interim)” issued and taking effect as of July 1!")
